AR104475A1 - MODIFIED FGF-21 POLIPEPTIDES AND ITS USES - Google Patents

MODIFIED FGF-21 POLIPEPTIDES AND ITS USES

Info

Publication number
AR104475A1
AR104475A1 ARP150103456A ARP150103456A AR104475A1 AR 104475 A1 AR104475 A1 AR 104475A1 AR P150103456 A ARP150103456 A AR P150103456A AR P150103456 A ARP150103456 A AR P150103456A AR 104475 A1 AR104475 A1 AR 104475A1
Authority
AR
Argentina
Prior art keywords
modified fgf
optionally
polipeptides
modified
polypeptides
Prior art date
Application number
ARP150103456A
Other languages
Spanish (es)
Inventor
Krupinski John
Camphausen Ray
Lipovsek Dasa
Christian Rose
Reilly Timothy
Mukherjee Ranjan
Cohen Daniel
Morin Paul
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR104475A1 publication Critical patent/AR104475A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Polipéptidos FGF-21 (factor de crecimiento de fibroblastos-21) modificados y sus usos, por ejemplo, para el tratamiento de enfermedades asociadas a la fibrosis. Se describen polipéptidos FGF-21 modificados que contienen una eliminación interna y opcionalmente un péptido de reemplazo, opcionalmente modificado con al menos un aminoácido codificado de manera no natural, y/u opcionalmente fusionado a un componente de fusión. Ácido nucleico; célula; método; composición.Modified FGF-21 polypeptides (fibroblast growth factor-21) and their uses, for example, for the treatment of fibrosis-associated diseases. Modified FGF-21 polypeptides containing an internal elimination and optionally a replacement peptide, optionally modified with at least one unnaturally encoded amino acid, and / or optionally fused to a fusion component are described. Nucleic acid; cell; method; composition.

ARP150103456A 2014-10-24 2015-10-23 MODIFIED FGF-21 POLIPEPTIDES AND ITS USES AR104475A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462068296P 2014-10-24 2014-10-24

Publications (1)

Publication Number Publication Date
AR104475A1 true AR104475A1 (en) 2017-07-26

Family

ID=59485540

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103456A AR104475A1 (en) 2014-10-24 2015-10-23 MODIFIED FGF-21 POLIPEPTIDES AND ITS USES

Country Status (1)

Country Link
AR (1) AR104475A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113289005A (en) * 2021-07-06 2021-08-24 温州医科大学 Application of rhFGF-21 in preparation of medicine for treating xerophthalmia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113289005A (en) * 2021-07-06 2021-08-24 温州医科大学 Application of rhFGF-21 in preparation of medicine for treating xerophthalmia
CN113289005B (en) * 2021-07-06 2022-05-31 温州医科大学 Application of rhFGF-21 in preparation of medicine for treating xerophthalmia

Similar Documents

Publication Publication Date Title
UY36370A (en) MODIFIED FGF-21 POLIPEPTIDES AND ITS USES
NI201800121A (en) GDF15 FUSION PROTEINS AND USES OF THEM
UY39119A (en) FUSION PROTEINS TO TREAT METABOLIC DISORDERS
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12017501115A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and method of use
EA202090931A3 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH HYBRID PROTEINS
CO2017000507A2 (en) Chimeric bcma antigen receptor
AR092456A1 (en) FUSION PROTEINS FOR THE TREATMENT OF A METABOLIC SYNDROME
AR092076A1 (en) HOMODIMERIC PROTEINS
ES2694667T3 (en) Method for producing oxalate oxidases having optical activity near physiological pH and use of such recombinant oxalate oxidases in the treatment of oxalate-related diseases
MX2020009371A (en) Compositions and methods for tcr reprogramming using fusion proteins.
ES2721309T3 (en) Composition for preparing tagatose and method for preparing tagatose from fructose
AR120721A2 (en) PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF JOINT DAMAGE
CO2017011431A2 (en) Variant epidermal growth factor receptor fusion proteins iii - mesothelin
CL2020000733A1 (en) Fusion protein comprising a portion of fgf-18.
EA201791918A1 (en) MODIFICATION OF PROTEINS OF CELL-OWNERS
AR104475A1 (en) MODIFIED FGF-21 POLIPEPTIDES AND ITS USES
BR112021011595A2 (en) Bispecific protein
MX2018003445A (en) Expression of fc-containing proteins.
CU20170036A7 (en) BLENDS THAT INCLUDE A PLURALITY OF POLYPEPTIDES WITH DEGRADING ACTIVITY OF BIOMASS AND METHODS TO PRODUCE THE SAME
AR117306A1 (en) POLYPEPTIDES HAVING PHYTASE ACTIVITY
AR114938A1 (en) EXPRESSION VARIANTS OF CDKL5 AND FUSION PROTEINS CDKL5
AR122764A2 (en) FORMULATION OF A FACTOR VIII POLYPEPTIDE, PHARMACEUTICAL KIT, METHOD
EA202092106A2 (en) MODIFIED FGF-21 POLYPEPTIDES AND THEIR APPLICATION
AR105615A1 (en) VARIOUS FUSIONS III OF THE EPIDERMAL-MESOTHELINE GROWTH FACTOR RECEIVER AND METHODS TO USE THE SAME

Legal Events

Date Code Title Description
FB Suspension of granting procedure